Top 3 Genomics Stocks to Consider for Your Portfolio

Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.

Zacks Investment Research • Nov 18, 2025

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.

Zacks Investment Research • Nov 11, 2025

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401's potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027 , enabling progression of EDIT-401 beyond initial human proof-of-concept data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2025 and provided business updates.

GlobeNewsWire • Nov 10, 2025

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.75 per share a year ago.

Zacks Investment Research • Nov 10, 2025

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025 to be held November 7-10 in New Orleans, Louisiana.

GlobeNewsWire • Nov 3, 2025

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Gene editing seems like a great idea: Instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as Crispr. I previously covered two companies, Crispr Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a Crispr licensee. But it failed twice, with treatments aimed at eye disease and sickle cell disease/beta thalassemia. And its stock suffered badly.

Seeking Alpha • Oct 14, 2025

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models

GlobeNewsWire • Oct 9, 2025

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.

GlobeNewsWire • Oct 6, 2025

Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 11, 2025

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.

Zacks Investment Research • Sep 3, 2025